Literature DB >> 20648559

Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.

Yan Ning1, Philipp C Manegold, Young Kwon Hong, Wu Zhang, Alexandra Pohl, Georg Lurje, Thomas Winder, Dongyun Yang, Melissa J LaBonte, Peter M Wilson, Robert D Ladner, Heinz-Josef Lenz.   

Abstract

Interleukin-8 (IL-8), a chemokine with a defining CXC amino acid motif, is known to possess tumorigenic and proangiogenic properties. Overexpression of IL-8 has been detected in many human tumors, including colorectal cancer (CRC), and is associated with poor prognosis. The goal of our study was to determine the role of IL-8 overexpression in CRC cells in vitro and in vivo. We stably transfected the IL-8 cDNA into two human colon cancer cell lines, HCT116 and Caco2, and selected IL-8-secreting transfectants. Real-time RT-PCR confirmed that IL-8 mRNA was overexpressed in IL-8 transfectants with 45- to 85-fold higher than parental cells. The IL-8-transfected clones secreted 19- to 28-fold more IL-8 protein than control and parental cells as detected by ELISA. The IL-8 transfectants demonstrated increased cellular proliferation, cell migration and invasion based on functional assays. Growth inhibition studies showed that IL-8 overexpression lead to a significant resistance to oxaliplatin (p < 0.0001). Inhibition of IL-8 overexpression with small interfering RNA reversed the observed increases in tumorigenic functions and oxaliplatin resistance, suggesting that IL-8 not only provides a proliferative advantage but also promotes the metastatic potential of colon cancer cells. Using a tumor xenograft model, IL-8-expressing cells formed significantly larger tumors than the control cells with increased microvessel density. Together, these findings indicate that overexpression of IL-8 promotes tumor growth, metastasis, chemoresistance and angiogenesis, implying IL-8 to be an important therapeutic target in CRC.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20648559      PMCID: PMC3039715          DOI: 10.1002/ijc.25562

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  49 in total

1.  Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique.

Authors:  G F Greene; Y Kitadai; C A Pettaway; A C von Eschenbach; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Cbl and Akt regulate CXCL8-induced and CXCR1- and CXCR2-mediated chemotaxis.

Authors:  Heather C Lane; Appakkudal R Anand; Ramesh K Ganju
Journal:  Int Immunol       Date:  2006-06-23       Impact factor: 4.823

3.  Interleukin-8 secretion by fibroblasts induced by low density lipoproteins is p38 MAPK-dependent and leads to cell spreading and wound closure.

Authors:  Iveta Dobreva; Gérard Waeber; Richard W James; Christian Widmann
Journal:  J Biol Chem       Date:  2005-10-26       Impact factor: 5.157

4.  Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I--an independent prognostic factor.

Authors:  J Kaminska; M P Nowacki; M Kowalska; A Rysinska; M Chwalinski; M Fuksiewicz; W Michalski; M Chechlinska
Journal:  Tumour Biol       Date:  2005-07-06

5.  Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.

Authors:  Wu Zhang; Jan Stoehlmacher; David J Park; Dongyun Yang; Erin Borchard; Ji Gil; Denice D Tsao-Wei; Jim Yun; Michael Gordon; Oliver A Press; Katrin Rhodes; Susan Groshen; Heinz-Josef Lenz
Journal:  Clin Colorectal Cancer       Date:  2005-07       Impact factor: 4.481

6.  Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials.

Authors:  A Li; M L Varney; R K Singh
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

7.  Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation.

Authors:  Michael A Gordon; Ji Gil; Bo Lu; Wu Zhang; Dongyun Yang; Jim Yun; Sylke Schneider; Susan Groshen; Syma Iqbal; Oliver A Press; Katrin Rhodes; Heinz-Josef Lenz
Journal:  Pharmacogenomics       Date:  2006-01       Impact factor: 2.533

8.  Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy.

Authors:  M M M Abdel-Latif; J M O'Riordan; N Ravi; D Kelleher; J V Reynolds
Journal:  Dis Esophagus       Date:  2005       Impact factor: 3.429

9.  Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma.

Authors:  Sabine Brennecke; Martin Deichmann; Helmut Naeher; Hjalmar Kurzen
Journal:  Melanoma Res       Date:  2005-12       Impact factor: 3.599

Review 10.  Cancer CXC chemokine networks and tumour angiogenesis.

Authors:  Robert M Strieter; Marie D Burdick; Javier Mestas; Brigitte Gomperts; Michael P Keane; John A Belperio
Journal:  Eur J Cancer       Date:  2006-02-28       Impact factor: 9.162

View more
  168 in total

1.  Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells.

Authors:  Wen-Xia Kuai; Qiong Wang; Xiao-Zhong Yang; Yao Zhao; Ren Yu; Xiao-Jun Tang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 2.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

3.  HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

Authors:  Simona di Martino; Carla Azzurra Amoreo; Barbara Nuvoli; Rossella Galati; Sabrina Strano; Francesco Facciolo; Gabriele Alessandrini; Harvey I Pass; Gennaro Ciliberto; Giovanni Blandino; Ruggero De Maria; Mario Cioce
Journal:  Oncogene       Date:  2018-01-09       Impact factor: 9.867

4.  Xiaotan Sanjie decoction inhibits interleukin-8-induced metastatic potency in gastric cancer.

Authors:  Jun Shi; Pin-Kang Wei
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

5.  Human leukemia differentiation factor (HLDF) controls the cytokine-producing function of blood cells in gastric adenocarcinomas.

Authors:  A V Sosnina; D V Morozov; N A Varaksin; A V Vonarshenko; L K Baidakova; A I Autenshlyus; V M Lipkin
Journal:  Dokl Biol Sci       Date:  2014-03-22

6.  Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.

Authors:  Yan Ning; Armin Gerger; Wu Zhang; Diana L Hanna; Dongyun Yang; Thomas Winder; Takeru Wakatsuki; Melissa J Labonte; Sebastian Stintzing; Nico Volz; Yu Sunakawa; Stefan Stremitzer; Rita El-Khoueiry; Heinz-Josef Lenz
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

7.  Thermal inkjet bioprinting triggers the activation of the VEGF pathway in human microvascular endothelial cells in vitro.

Authors:  Luis H Solis; Yoshira Ayala; Susana Portillo; Armando Varela-Ramirez; Renato Aguilera; Thomas Boland
Journal:  Biofabrication       Date:  2019-07-09       Impact factor: 9.954

8.  Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation.

Authors:  Eun Sun Jang; Jung-Hwan Yoon; Sung-Hee Lee; Soo-Mi Lee; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-27       Impact factor: 4.553

9.  Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.

Authors:  Sivapriya Ponnurangam; David Standing; Parthasarathy Rangarajan; Dharmalingam Subramaniam
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

10.  CXCL8, IL-1β and sCD200 are pro-inflammatory cytokines and their levels increase in the circulation of breast carcinoma patients.

Authors:  Betul Celik; Arzu Didem Yalcin; Gizem Esra Genc; Tangul Bulut; Sibel Kuloglu Genc; Saadet Gumuslu
Journal:  Biomed Rep       Date:  2016-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.